Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.04
+0.2%
$48.06
$39.35
$63.33
$95.49B0.3812.92 million shs14.54 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$38.66
+1.0%
$38.69
$31.72
$44.67
$78.33B0.524.92 million shs4.82 million shs
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Zoetis Inc. stock logo
ZTS
Zoetis
$157.76
+0.3%
$159.89
$139.70
$200.33
$70.05B0.942.56 million shs4.55 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.14%-0.45%+0.33%-20.51%+11.39%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+1.03%-2.61%-0.10%+0.97%-4.67%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%0.00%
Zoetis Inc. stock logo
ZTS
Zoetis
+0.16%-2.40%-3.17%-2.95%-8.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4.9451 of 5 stars
3.25.04.24.03.03.31.3
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.3051 of 5 stars
1.14.02.50.02.70.02.5
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
1.1602 of 5 stars
0.00.00.03.20.61.71.9
Zoetis Inc. stock logo
ZTS
Zoetis
4.6583 of 5 stars
3.53.04.20.43.42.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.32
Hold$58.0023.31% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$37.38-3.31% Downside
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00
N/AN/AN/A
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$212.1334.46% Upside

Current Analyst Ratings Breakdown

Latest ZTS, HZNP, BMY, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$165.00 ➝ $160.00
6/3/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/12/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/7/2025
Zoetis Inc. stock logo
ZTS
Zoetis
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$189.00 ➝ $170.00
4/28/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/23/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $68.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
4/15/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$35.25
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.30B1.98$5.90 per share7.97$8.08 per share5.82
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B1.97$5.63 per share6.86$8.07 per share4.79
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Zoetis Inc. stock logo
ZTS
Zoetis
$9.26B7.59$7.09 per share22.25$10.57 per share14.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.6717.627.721.3911.38%87.62%15.98%7/31/2025 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$1.9419.938.311.349.89%48.82%11.15%7/30/2025 (Estimated)
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.49B$5.5728.3223.372.6127.12%55.48%19.14%8/5/2025 (Estimated)

Latest ZTS, HZNP, BMY, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.40$1.48+$0.08$1.41$2.20 billion$2.22 billion
4/30/2025Q1 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion
4/24/2025Q1 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.27%N/A92.88%17 Years
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.694.37%N/A87.11%N/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.001.27%N/A35.91%14 Years

Latest ZTS, HZNP, BMY, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2025
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.501.2%7/18/20257/18/20259/3/2025
6/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.25%7/3/20257/3/20258/1/2025
5/2/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42164.1%5/16/20255/16/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.65
1.28
1.17
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.21
0.87
0.58
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Zoetis Inc. stock logo
ZTS
Zoetis
1.12
1.74
1.04

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.07%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Zoetis Inc. stock logo
ZTS
Zoetis
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.05 billion1.84 billionOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
13,800445.21 million444.50 millionOptionable

Recent News About These Companies

ZTS - Zoetis Inc Class A Ownership - Morningstar
Infosys announces strategic collaboration with Zoetis
2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$47.04 +0.12 (+0.25%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$47.18 +0.15 (+0.32%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK stock logo

GSK NYSE:GSK

$38.66 +0.40 (+1.03%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$38.60 -0.05 (-0.14%)
As of 04:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Horizon Therapeutics Public stock logo

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Zoetis stock logo

Zoetis NYSE:ZTS

$157.76 +0.42 (+0.27%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$158.52 +0.77 (+0.49%)
As of 06/24/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.